The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Search
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Boehringer Ingelheim good 2021 business performance
2021 was a good year for patients, for animal owners and for Boehringer Ingelheim.
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Facts about the INPULSIS™ trials
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis